Questcor Pharmaceuticals (QCOR +10.1%) jumps after releasing June prescription data for its...


Questcor Pharmaceuticals (QCOR +10.1%) jumps after releasing June prescription data for its Acthar gel. Paid Acthar prescriptions for treating nephrotic syndrome rose to 115-120 in June from 103 in May, prescriptions for treating multiple sclerosis rose to 400-410 from 365, and prescriptions for treating infantile spasms came in at 30-35, compared with 32 in May. It's added Questcor repurchased $156.1M worth of shares in Q2 at an average price of $41.85.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs